MAFG-AS1 is a prognostic biomarker and facilitates prostate cancer progression

Peizhang Li; Yuanping Shi; Miaomiao Guo; Miaomiao Guo; Huan Xu; Ming Zhan; Zhong Wang; Yanbo Chen

doi:10.3389/fonc.2022.856580

Frontiers in Oncology (Aug 2022)

MAFG-AS1 is a prognostic biomarker and facilitates prostate cancer progression

Peizhang Li,
Yuanping Shi,
Miaomiao Guo,
Miaomiao Guo,
Huan Xu,
Ming Zhan,
Zhong Wang,
Yanbo Chen

Affiliations

Peizhang Li: Department of Urology, Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
Yuanping Shi: Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China
Miaomiao Guo: The Core Laboratory in Medical Center of Clinical Research, Department of Molecular Diagnostics and Endocrinology, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Miaomiao Guo: Department of Molecular Diagnostics, Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
Huan Xu: Department of Urology, Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
Ming Zhan: Department of Urology, Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
Zhong Wang: Department of Urology, Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
Yanbo Chen: Department of Urology, Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China

DOI: https://doi.org/10.3389/fonc.2022.856580
Journal volume & issue: Vol. 12

Abstract

Read online

Long Noncoding RNAs (LncRNAs) have recently been identified as key regulator in tumor progression. The LncRNA MAFG-AS1 has been reported to facilitate the progression of multiple cancers, however, its role in prostate cancer is still unknown. Here, we reported that MAFG-AS1 was upregulated in prostate cancer. Importantly, high expression of MAFG-AS1 indicated advanced stage prostate cancer. Univariate and Multivariate Cox regression analyses showed that high MAFG-AS1 expression was independently correlated with poor progression-free interval (PFI). According to the result of The Cancer Genome Atlas (TCGA) database and tissue microarray, high MAFG-AS1 expression indicated a poor prognosis in prostate cancer patients. In addition, gene functional enrichment analysis revealed that MAFG-AS1 may be involved in ribosome biogenesis, ribonucleoprotein complex subunit organization, ribonucleoprotein complex assembly, rRNA metabolic process, structural constituent of ribosome, and ribonucleoprotein complex binding. Furthermore, MAFG-AS1 knockdown by siRNA markedly impaired prostate cancer cell proliferation, migration, and invasion.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords